The Intensive Care Unit



Caring for patients in the intensive care unit demands constant, meticulous thought and consideration while implementing every aspect of their management. Among the many life-sustaining therapies provided for those in the intensive care unit (ICU), the use of an individually tailored pharmacologic regimen has the potential to dramatically improve the overall health of the patient as well as to do great harm. Severe derangements in the physiologic responses and homeostatic mechanisms of critically ill patients often times result in challenges in constructing a durable therapeutic regimen. At times, these alterations in function can be difficult to detect, and their effects on the intended action of pharmacologic substances are often impossible to quantify. Knowledge of these specific disease processes, their potential effects on pharmacodynamics and pharmacokinetics, as well as an intimate familiarity with the pharmacologic agents most often used in the intensive care unit can lead to an optimized approach to improving the health of the critically ill patient.


Traumatic Brain Injury Critical Illness Intensive Care Unit Patient Hepatic Blood Flow Cerebral Vasospasm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Mihic SJ, Harris RA. Chapter 17: Hypnotics and sedatives. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s The pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill; 2011.Google Scholar
  2. 2.
    Oldenhof H, et al. Clinical pharmacokinetics of midazolam in intensive care patients, a wide interpatient variability[quest]. Clin Pharmacol Ther. 1988;43(3):263–9.PubMedCrossRefGoogle Scholar
  3. 3.
    Malacrida R, et al. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med. 1992;20(8):1123–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med. 1998;26(5):947–56.PubMedCrossRefGoogle Scholar
  5. 5.
    Bray RJ. Propofol infusion syndrome in children. Pediatr Anesth. 1998;8(6):491–9.CrossRefGoogle Scholar
  6. 6.
    Wolf A, et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet. 2001;357(9256):606–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Kam PCA, Cardone D. Propofol infusion syndrome. Anaesthesia. 2007;62(7):690–701.PubMedCrossRefGoogle Scholar
  8. 8.
    DeChicco R, et al. Contribution of calories from propofol to total energy intake. J Am Diet Assoc. 1995;95(9):A25.CrossRefGoogle Scholar
  9. 9.
    Laulin J-P, et al. The role of ketamine in preventing fentanyl-induced hyperalgesia and subsequent acute morphine tolerance. Anesth Analg. 2002;94(5):1263–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Riker RR, Shehabi Y, Bokesch PM, et al. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009;301(5):489–99.PubMedCrossRefGoogle Scholar
  11. 11.
    Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151–60.PubMedCrossRefGoogle Scholar
  12. 12.
    Mukhtar AM, Obayah EM, Hassona AM. The use of dexmedetomidine in pediatric cardiac surgery. Anesth Analg. 2006;103(1):52–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Shehabi Y, et al. Prevalence of delirium with dexmedetomidine compared with morphine based therapy after cardiac surgery: a randomized controlled trial (DEXmedetomidine COmpared to Morphine-DEXCOM study). Anesthesiology. 2009;111(5):1075–84. doi: 10.1097/ALN.0b013e3181b6a783.PubMedCrossRefGoogle Scholar
  14. 14.
    Dellinger RP, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med. 2013;39(2):165–228.PubMedCrossRefGoogle Scholar
  15. 15.
    Russell JA, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358(9):877–87.PubMedCrossRefGoogle Scholar
  16. 16.
    Zewail AM, et al. Intravenous milrinone in treatment of advanced congestive heart failure. Tex Heart Inst J. 2003;30(2):109–13.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Barker FG, Ogilvy CS. Efficacy of prophylactic nimodipine for delayed ischemic deficit after subarachnoid hemorrhage: a metaanalysis. J Neurosurg. 1996;84(3):405–14.PubMedCrossRefGoogle Scholar
  18. 18.
    McGarry L, Stokes M, Thompson D. Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thromb J. 2006;4(1):17.PubMedCentralPubMedCrossRefGoogle Scholar
  19. 19.
    Kakkar AK, et al. Low-molecular-weight heparin and mortality in acutely ill medical patients. N Engl J Med. 2011;365(26):2463–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Yoshida Rde A, et al. Systematic review of randomized controlled trials of new anticoagulants for venous thromboembolism prophylaxis in major orthopedic surgeries, compared with enoxaparin. Ann Vasc Surg. 2013;27(3):355–69.PubMedCrossRefGoogle Scholar
  21. 21.
    Annane D, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862–71.PubMedCrossRefGoogle Scholar
  22. 22.
    Sprung CL, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111–24.PubMedCrossRefGoogle Scholar
  23. 23.
    Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol. 2010;23(6):597–602. doi: 10.1097/WCO.0b013e32833e5a5d.PubMedCrossRefGoogle Scholar
  24. 24.
    Bebawy JF. Perioperative steroids for peritumoral intracranial edema: a review of mechanisms, efficacy, and side effects. J Neurosurg Anesthesiol. 2012;24(3):173–7. doi: 10.1097/ANA.0b013e3182578bb5.PubMedCrossRefGoogle Scholar
  25. 25.
    Feigin VL, et al. Corticosteroids in patients with hemorrhagic stroke. Stroke. 2006;37(5):1344–5.CrossRefGoogle Scholar
  26. 26.
    Collaborators CT. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury? Outcomes at 6 months. Lancet. 2005;365(9475):1957–9.CrossRefGoogle Scholar
  27. 27.
    Cook DJ, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med. 1994;330(6):377–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Marik PE, et al. Stress ulcer prophylaxis in the new millennium: a systematic review and meta-analysis. Crit Care Med. 2010;38(11):2222–8. doi: 10.1097/CCM.0b013e3181f17adf.PubMedCrossRefGoogle Scholar
  29. 29.
    Lin PC, et al. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: a meta-analysis. Crit Care Med. 2010;38(4):1197–205.PubMedCrossRefGoogle Scholar
  30. 30.
    Alhazzani W, et al. Proton pump inhibitors versus histamine 2 receptor antagonists for stress ulcer prophylaxis in critically ill patients: a systematic review and meta-analysis*. Crit Care Med. 2013;41(3):693–705. doi: 10.1097/CCM.0b013e3182758734.PubMedCrossRefGoogle Scholar
  31. 31.
    Sreedharan A, et al. Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding. Cochrane Database Syst Rev. 2010;(7):CD005415.Google Scholar
  32. 32.
    Wang C, Ma MH, Chou HC, et al. High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2010;170(9):751–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Songür Y, et al. Comparison of infusion or low-dose proton pump inhibitor treatments in upper gastrointestinal system bleeding. Eur J Intern Med. 2011;22(2):200–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  1. 1.Department of AnesthesiaHarvard Medical SchoolBostonUSA
  2. 2.Department of Anesthesia, Critical Care and Pain MedicineBeth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations